Biogen Beats Estimates as New Medicines Overtake MS Business
Earnings·1 article across 1 outlet
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Biogen Inc. reported quarterly revenue and adjusted earnings that beat analysts’ expectations as sales of newly acquired kidney and eye-disease drugs helped offset declining revenue from multiple sclerosis medicines.
The company's performance highlights the impact of its new product lines, which have contributed significantly to growth despite challenges in its traditional multiple sclerosis business.
Biogen
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Biogen Inc. reported quarterly revenue and adjusted earnings that beat analysts’ expectations as sales of newly acquired kidney and eye-disease drugs helped offset declining revenue from multiple sclerosis medicines.”
Bloomberg — Biogen Beats Estimates as New Medicines Overtake MS Business
SupportCorroborates it
“Biogen beats quarterly estimates as newer drugs fuel growth”
Yahoo Finance — Biogen beats quarterly estimates as newer drugs fuel growth